Table 1.
Clinicaltrials.gov identifiers of clinical trials that are assessing emerging technologies for personalized and precision medicine.
| Technology Platform | Status | Key Details of Study | Clinicaltrials.gov Identifier |
|---|---|---|---|
| Artificial Intelligence | Phase II | Harnessing CURATE.AI to optimize N-of-1 combination therapy in multiple myeloma | NCT03759093 |
| Artificial Intelligence | Interventional | Developing N-of-1 training trajectories via CURATE.AI | NCT03832101 |
| Artificial Intelligence | Phase IV | Human Immunodeficiency Virus (HIV): Optimization of dose reduction of Tenofovir (TDF) in antiretroviral therapy (ART). | NCT02632474 |
| Artificial Intelligence | Phase II | Liver and kidney transplant: Dynamic modulation of therapeutic dosing to optimize immunosuppression. | NCT03527238 |
| Artificial Intelligence | Interventional | Radiotherapy: Image-guided adaptive radiotherapy is being studied to modulate intensity to reduce side effects and improve outcomes. | NCT04022018 |
| Genomic Analysis/Companion Diagnostics |
Feasibility | Non-small cell lung cancer (NSCLC): Co-clinical trials with genetic mouse models, NSCLC patient specimens (plasma, serum, tissue), and healthy patient samples to develop liquid biopsies. | NCT02597738 |
| Genome-Guided Therapy | Observational | Pain: Assessment of the cytochrome P450 2D6 (CYP2D6) and μ-opioid receptor gene (OPRM1) genoypes in guiding pain management. | NCT02664350 |
| Genome-Guided Therapy | Observational | Preterm birth: Genomic profiling to predict patient response to 17 hydroxyprogesterone caproate (17OHPC) therapy to prevent preterm birth | NCT02173210 |
| Genome-Guided Therapy | Phase II | Breast cancer: Biomarker analysis and genetic screening to develop individualized treatment regimens. | NCT02624973 |
| Genome-Guided Therapy | Phase II | Multiple tumor types: Matching of drugs to patients based on genomic alterations. | NCT02795156 |
| Genome-Guided Therapy | Phase III | Prostate cancer: Circulating tumor DNA is being used as a biomarker for genome-guided drug selection. | NCT03903835 |
| Microfluidics/Companion Diagnostics | Observational | Multiple Cancer Types/Circulating Tumor Cells: Correlation of titre with treatment response and progression for nasopharyneal carcinoma, breast cancer, colorectal cancer, prostate cancer, and gastric cancer | NCT01022723 |
| Microfluidics/Companon Diagnostics | Observational | Clear Cell Renal Cancer/Circulating Tumor Cells: Comparison of microfluidic technology that can detect CTCs under low epithelial cell adhesion molecule (EpCAM) presence compared to EpCAM-based detection platform for clear cell renal cancer. | NCT02499458 |
| Microfluidics/Companion Diagnostics | Observational | Metastatic Breast Cancer/Circulating Tumor Cells: Application of antibody cocktails to capture CTCs from metastatic breast cancer for microfluidic analysis. | NCT02904135 |
| Genome Editing | Phase I | Mucopolysaccharidosis II (MPS II): Intravenous delivery of SB-913, a zinc finger nuclease, to enable production of Iduronate 2-Sulfatase (IDS) enzyme from the liver. | NCT03041324 |
| Genome Editing | Phase I | Mucopolysaccharidosis I (MPS I): Intravenous delivery of SB-318, a zinc finger nuclease, to insert α-L-iduronidase (IDUA) gene to enable liver-mediated enzyme production. | NCT02702115 |
| Genome Editing | Phase I | Severe Hemophilia: Intravenous delivery of SB-FIX, a zinc finger nuclease, to insert the SB-FIX gene to enable Factor IX clotting factor production. | NCT02695160 |
| Genome Editing/Cell Therapy | Phase I | Human Immunodeficiency Virus (HIV): Administration of zinc finger nuclease CCR5-modified hematopoietic stem/progenitor cells (SB-728mR-HSPC) in patients with undetectable disease/low CD4+ counts. | NCT02500849 |
| Nanomedicine/RNA Therapy | Phase 0 | Glioblastoma: Administration of NU-0129, a spherical nucleic acid (SNA) therapy to target the Bcl2L12 gene to arrest tumor growth. | NCT03020017 |
| Nanomedicine | Phase I | Cervical cancer: Polysiloxane gadolinium chelates are delivered in combination with cisplatin and radiation therapy to address locally advanced disease. | NCT03308604 |
| Wearables | Observational | Perioperative Risk Assessment: Pairing wearable (Garmin VivoSmart HR+) with cardiopulmonary exercise testing (CPET) indicators to develop broadly applicable risk assessment protocol for high-risk elective surgery patient population. | NCT03328039 |
| Wearables | Observational | Chronic obstructive airway disease (COPD): Application of wearable on finger for heart rate variability and oxygen saturation to detect and manage COPD in patients over 60 years in age. | NCT03268538 |
| Wearables | Observational | Cardiology: A shirt-based electrocardiogram (ECG) system is being used to monitor the following patient cohorts: 1) Cardiac rehabilitation following myocardial infarct; 2) Pediatric superventricular tachycardia (SVT); 3) Post-pulmonary vein isolation (PVI); 4) Cardiac resynchronization therapy patients. |
NCT03068169 |
| Digital Health | Observational | Alzheimer’s Disease: Cognitive battery software was used to predict dementia onset. | NCT03676881 |
| Digital Health | Interventional | Health eBrain Study: Application of neurocognitive assessment mobile health software to assess brain health combined with Mindoula intervention to address dementia and depression in Alzheimer’s Disease caregivers. | NCT02903862 |
| Biomaterials | Phase II | Wound healing: A nanodiamond-based biomaterial platform to mediate peri-apical wound healing and prevention of re-infection following root canal therapy. | NCT03376984 |
| Biomaterials | Phase I | 3-D Printing: Personalized 3-D printing of polycaprolactone (PCL) is being explored for breast reconstruction after tumor removal. | NCT03348293 |
| Electronic Health Records/Infrastructure/ Genotyping |
Observational | Pain: CYP2D6 genotyping for pain management/control and integration of pain questionnaire in electronic health record for physician guidance. | NCT02335307 |